SOMERSET, N.J. and GOSSELIES, BELGIUM — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for
Maculus Therapeutix, a preclinical-stage biopharmaceutical company which has developed a SINGLE injection delivery platform for diseases such as wet AMD